Pub. Date : 2013
PMID : 24265554
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. | Rosuvastatin Calcium | component of oligomeric golgi complex 2 | Homo sapiens |
| 2 | RESULTS: LDL-C reductions from baseline and goal attainment improved substantially in patients treated with ezetimibe added onto simvastatin, atorvastatin, or rosuvastatin therapy (n=2,312) versus those (n=13,053) who titrated these statins. | Rosuvastatin Calcium | component of oligomeric golgi complex 2 | Homo sapiens |
| 3 | In multivariable models, percent change from baseline in LDL-C was -13.1% to -14.8% greater for those who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus those who titrated. | Rosuvastatin Calcium | component of oligomeric golgi complex 2 | Homo sapiens |
| 4 | The odds of attaining LDL-C<1.8 and <2.6 mmol/L (70 and 100 mg/dL) increased by 2.6-3.2-fold and 2.5-3.1-fold, respectively, in patients who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin versus titrating statins. | Rosuvastatin Calcium | component of oligomeric golgi complex 2 | Homo sapiens |
| 5 | CONCLUSION: CHD/CHD risk-equivalent patients in a large US managed-care database, who added ezetimibe onto simvastatin, atorvastatin, or rosuvastatin, had greater LDL-C reductions and goal attainment than those who uptitrated these statin therapies. | Rosuvastatin Calcium | component of oligomeric golgi complex 2 | Homo sapiens |